<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061693</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-206</org_study_id>
    <nct_id>NCT05061693</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of INCB054707 in&#xD;
      participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment&#xD;
      period, followed by a 24 -week single blind extension period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">June 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving ≥ 4-point improvement in Itch Numerical Rating Scale (NRS) score</measure>
    <time_frame>Week 16</time_frame>
    <description>Itch NRS is an 11-point scale (0 to10) where 0 is &quot;no itch&quot; and 10 is the &quot;worst itch imaginable&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Investigator's Global Assessment Treatment Success (IGA-TS)</measure>
    <time_frame>Week 16</time_frame>
    <description>Defined as IGA score of 0 or 1 with a ≥ 2-grade improvement from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ≥ 4-point improvement from baseline in Itch NRS score</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Defined as time taken for the participant to achieve a ≥4 improvement in NRS scale compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Prurigo Nodularis</condition>
  <arm_group>
    <arm_group_label>INCB054707 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB054707 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB054707 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by INCB054707 Dose B or C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>INCB054707 Dose A</arm_group_label>
    <arm_group_label>INCB054707 Dose B</arm_group_label>
    <arm_group_label>INCB054707 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>Placebo followed by INCB054707 Dose B or C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of PN for at least 3 months before screening.&#xD;
&#xD;
          -  Inadequate response or intolerant to ongoing or prior PN therapy.&#xD;
&#xD;
          -  ≥ 20 nodules on ≥ 2 different body regions at screening and Day 1.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children&#xD;
&#xD;
          -  Further inclusion criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have chronic pruritus due to a condition other than PN; have neuropathic and&#xD;
             psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial&#xD;
             pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis.&#xD;
&#xD;
          -  Current use of a medication known to cause pruritus.&#xD;
&#xD;
          -  Women who are pregnant (or who are considering pregnancy) or lactating.&#xD;
&#xD;
          -  Medical history including thrombocytopenia, coagulopathy or platelet dysfunction,&#xD;
             Q-wave interval abnormalities, current or history of certain infections, cancer,&#xD;
             lymphoproliferative disorders and other medical conditions at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Have evidence of active or latent or inadequately treated infection with Mycobacterium&#xD;
             tuberculosis.&#xD;
&#xD;
          -  Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.&#xD;
&#xD;
          -  Laboratory values outside of the protocol-defined ranges.&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigative Site US001</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US006</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US004</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US002</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US005</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prurigo nodularis</keyword>
  <keyword>PN</keyword>
  <keyword>INCB054707</keyword>
  <keyword>chronic pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

